These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 31299468)

  • 1. Genetic effects on efficacy to fluticasone propionate/salmeterol treatment in COPD.
    Condreay LD; Qu XA; Anderson J; Compton C; Ghosh S
    Respir Med; 2019 Aug; 155():51-53. PubMed ID: 31299468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study.
    Vogelmeier C; Paggiaro PL; Dorca J; Sliwinski P; Mallet M; Kirsten AM; Beier J; Seoane B; Segarra RM; Leselbaum A
    Eur Respir J; 2016 Oct; 48(4):1030-1039. PubMed ID: 27492833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.
    Donohue JF; Worsley S; Zhu CQ; Hardaker L; Church A
    Respir Med; 2015 Jul; 109(7):870-81. PubMed ID: 26006754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
    Beeh KM; Derom E; Echave-Sustaeta J; Grönke L; Hamilton A; Zhai D; Bjermer L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():193-205. PubMed ID: 26893551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chinese Herbal Medicine and Salmeterol and Fluticasone Propionate for Chronic Obstructive Pulmonary Disease: Systematic Review and Network Meta-Analysis.
    Chung VCH; Wu X; Ma PHX; Ho RST; Poon SK; Hui DS; Wong SYS; Wu JCY
    Medicine (Baltimore); 2016 May; 95(20):e3702. PubMed ID: 27196484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
    Kurashima K; Hara K; Yoneda K; Kanauchi T; Kagiyama N; Tokunaga D; Takayanagi N; Ubukata M; Sugita Y
    Respirology; 2009 Mar; 14(2):239-44. PubMed ID: 19210650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study.
    Jung KS; Park HY; Park SY; Kim SK; Kim YK; Shim JJ; Moon HS; Lee KH; Yoo JH; Lee SD; ;
    Respir Med; 2012 Mar; 106(3):382-9. PubMed ID: 21975275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
    Zheng JP; Yang L; Wu YM; Chen P; Wen ZG; Huang WJ; Shi Y; Wang CZ; Huang SG; Sun TY; Wang GF; Xiong SD; Zhong NS
    Chest; 2007 Dec; 132(6):1756-63. PubMed ID: 17951625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial.
    Singh D; Worsley S; Zhu CQ; Hardaker L; Church A
    BMC Pulm Med; 2015 Aug; 15():91. PubMed ID: 26286141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes.
    Anzueto A; Ferguson GT; Feldman G; Chinsky K; Seibert A; Emmett A; Knobil K; O'Dell D; Kalberg C; Crater G
    COPD; 2009 Oct; 6(5):320-9. PubMed ID: 19863361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD.
    O'Donnell DE; Sciurba F; Celli B; Mahler DA; Webb KA; Kalberg CJ; Knobil K
    Chest; 2006 Sep; 130(3):647-56. PubMed ID: 16963658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the efficacy and safety of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler versus a multi-dose inhaler in patients with chronic obstructive pulmonary disease.
    Chan R; Sousa AR; Hynds P; Homayoun-Valiani F; Edwards D; Tabberer M
    Pulm Pharmacol Ther; 2017 Apr; 43():12-19. PubMed ID: 28115223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of yiqibushenhuoxue decoction on chronic obstructive pulmonary disease measured by St. George's respiratory disease questionnaire scores and forced expiratory volume.
    Liu J; Gao F; Li Z
    J Tradit Chin Med; 2014 Aug; 34(4):445-9. PubMed ID: 25185362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD.
    Vestbo J; Soriano JB; Anderson JA; Calverley P; Pauwels R; Jones P;
    Respir Med; 2004 Nov; 98(11):1045-50. PubMed ID: 15526804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
    Dransfield MT; Feldman G; Korenblat P; LaForce CF; Locantore N; Pistolesi M; Watkins ML; Crim C; Martinez FJ
    Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
    Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
    Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting.
    Rutten-van Mölken M; Roos B; Van Noord JA
    Thorax; 1999 Nov; 54(11):995-1003. PubMed ID: 10525558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD.
    Agustí A; de Teresa L; De Backer W; Zvarich MT; Locantore N; Barnes N; Bourbeau J; Crim C
    Eur Respir J; 2014 Mar; 43(3):763-72. PubMed ID: 24114969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No genetic associations with mepolizumab efficacy in COPD with peripheral blood eosinophilia.
    Condreay LD; Gao C; Bradford E; Yancey SW; Ghosh S
    Respir Med; 2019 Aug; 155():26-28. PubMed ID: 31295674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD.
    Schermer TR; Albers JM; Verblackt HW; Costongs RJ; Westers P
    Fam Pract; 2007 Apr; 24(2):181-8. PubMed ID: 17251178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.